U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07889193) titled 'Phase I Clinical Trial of Trivalent Inactivated Split Influenza Virus Vaccine (MDCK Cell)' on Oct. 15.
Brief Summary: This study is a phase I, randomized, double-blind, placebo and active comparator-controlled clinical trial to evaluate the safety and immunogenicity of a trivalent split influenza virus vaccine (MDCK cell) developed by Sinovac Biotech Co., Ltd., in participants aged 6 months and above.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Seasonal Influenza
Intervention:
BIOLOGICAL: Cell-based Trivalent Split Influenza Virus Vaccine (cTIV)
Investigational trivalent split influenza virus vaccine pr...